Stock 4568 DAIICHI SANKYO CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Daiichi Sankyo Co., Ltd.

Equities

4568

JP3475350009

Market Closed - Japan Exchange
Other stock markets
 02:00:00 2024-04-26 am EDT 		5-day change 1st Jan Change
5,010 JPY +5.12% Intraday chart for Daiichi Sankyo Co., Ltd. +8.07% +29.39%
Apr. 25 Scholz pledges further support for the pharmaceutical industry DP
Apr. 25 Daiichi Sankyo's Attributable Profit Soars 84% in Fiscal 2024 MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Scholz pledges further support for the pharmaceutical industry
DP
Daiichi Sankyo's Attributable Profit Soars 84% in Fiscal 2024
MT
AstraZeneca upbeat as cancer drugs underpin sales growth
AN
Daiichi Sankyo Company, Limited announces an Equity Buyback for 55,000,000 shares, representing 2.87% for ¥200,000 million.
CI
Daiichi Sankyo Company, Limited authorizes a Buyback Plan.
CI
Roche’s HER2-Low Metastatic Breast Cancer Diagnostic Test Secures CE Mark
MT
AstraZeneca hails neurological data for Ultomiris, Soliris
AN
Astrazeneca and Daiichi Sankyo's ENHERTU Receives Approval in US as First Tumor-Agnostic HER2-Directed Therapy for Previously Treated Patients with Metastatic HER2-Positive Solid Tumors
CI
US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors
RE
Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer
CI
AstraZeneca, Daiichi make US progress with licence approvals
AN
FTSE 100 Ends Lower; UK Manufacturing Sector Escapes Contraction
MT
AstraZeneca and Daiichi make US progress with latest licence approvals
AN
AstraZeneca, Daiichi Sankyo Seek US FDA Approval for Breast Cancer Drug
MT
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
CI
Final dividend
FA
Esperion, Daiichi Get EU Committee Recommendation For Nilemdo, Nustendi Label Update
MT
Japan's Nikkei slips as techs track US peers lower; BOJ decision in focus
RE
UK's MHRA Approves Quizartinib To Treat Adult Patients With Acute Myeloid Leukaemia
RE
AstraZeneca's breast cancer treatment blocked for NHS use in England
AN
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4568 Stock
  4. News Daiichi Sankyo Co., Ltd.
  5. Highlights